Synairgen is a specialist respiratory biotech company whose primary focus is developing our investigative candidate SNG001 (inhaled interferon beta) to meet the urgent need for the treatment of COVID-19 and other severe viral lung infections as potentially the first host-targeted broad-spectrum antiviral treatment delivered directly into the lungs.
Our Phase 3 clinical trial is currently evaluating nebulised SNG001 in hospitalised COVID-19 patients across 17 countries. In a Phase 2 trial in hospitalised COVID-19 patients, SNG001 demonstrated a greater than twofold chance of recovery to ‘no limitation of activities’ versus placebo.
Founded by University of Southampton (UK) Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic in 2003, Synairgen is quoted on AIM (LSE: SNG). For more information, please visit www.synairgen.com.
Our Phase 3 clinical trial is currently evaluating nebulised SNG001 in hospitalised COVID-19 patients across 17 countries. In a Phase 2 trial in hospitalised COVID-19 patients, SNG001 demonstrated a greater than twofold chance of recovery to ‘no limitation of activities’ versus placebo.
Founded by University of Southampton (UK) Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic in 2003, Synairgen is quoted on AIM (LSE: SNG). For more information, please visit www.synairgen.com.
Location: United Kingdom, England, Southampton
Employees: 51-200
Phone: +44 23 8051 2800
Founded date: 2003
Mentions in press and media 24
| Date | Title | Description |
| 09.05.2025 | Tech Titans in Transition: EPAM and FD Technologies Navigate New Waters | The tech landscape is shifting. Companies are adapting, evolving, and sometimes, transforming entirely. Two recent stories highlight this dynamic: EPAM Systems and FD Technologies. Both firms are at pivotal moments, reshaping their futures ... |
| 07.05.2025 | FD Technologies shares surge on US takeover offer | Shares in Newry-based tech firm FD Technologies rocketed on Wednesday as its odds of a US takeover increased. The AIM-listed company’s board of directors issued a statement on Wednesday addressing offers of a takeover from US private equity... |
| 22.02.2022 | Biotech shares eviscerated in wake of Covid-19 flop | When Southampton, UK-based Synairgen last updated its investors, CEO Richard Marsden spotlighted the progress it’s making on the Phase III SPRINTER trial for the lead candidate, SNG001, an inhaled interferon beta formula... |
| 07.12.2021 | Synairgen : 7th December 2021 ESWI presentation demonstrates interferon beta has potent antiviral activity against SARS-CoV-2 including variants of concern | Press release Synairgen plc ('Synairgen' or the 'Company') Posting of Annual Report and Accounts and Notice of Annual General Meeting Southampton, UK - 25 May 2021: Synairgen plc (LSE: SNG), the respiratory company developing inhaled interf... |
| 11.11.2021 | 11th November 2021 Synairgen completes Phase III recruitment | Press Release Synairgen plc ('Synairgen' or the 'Company') Synairgen completes recruitment in its international Phase 3 SPRINTER study of SNG001 in hospitalised COVID-19 patients Target of 610 patients from 17 countries achieved Synairgen r... |
| 20.10.2021 | Synairgen : 20th October 2021 SNG001 progresses to Phase 3 of ACTIV-2 trial | Synairgen plc ('Synairgen' or the 'Company') Synairgen announces its inhaled interferon beta (SNG001) is advancing to Phase 3 of the NIH-sponsored ACTIV-2COVID-19 Trial Southampton, UK - 20 October 2021: Synairgen plc (LSE: SNG), the respir... |
| 13.10.2021 | Synairgen : 13th October 2021 Synairgen appoints Gareth Walters, Ph.D. as Chief Regulatory Officer | Synairgen plc ('Synairgen' or the 'Company') Synairgen announces the appointment of Gareth Walters, Ph.D. as Chief Regulatory Officer Brings more than 30 years of experience in the pharmaceutical and biotech industries and a deep understand... |
| 11.10.2021 | The first-ever COVID-19 pill may be just weeks away. A handful of other pills, inhalers, and nasal sprays also show promise. | A man holds a capsule. Photographer, Basak Gurbuz Derman/Getty Images Treating COVID-19 could be simpler soon, thanks to the next generation of treatments. These could come in the form of pills, nasal sprays, or inhalers. On Monday, Merck a... |
| 30.09.2021 | Synairgen : 30th September 2021 Interim results for the six months ended 30 June 2021 | Synairgen plc ('Synairgen' or the 'Company') Interim results for the six months ended 30 June 2021 Scaling up and preparing for Phase III COVID-19 trial data read-out Webcast today at 13:00 BST Southampton, UK - 30 September 2021: Synairgen... |
| 25.05.2021 | SYNAIRGEN PLC Synairgen : 25th May 2021 2020 Annual Report | Annual Report a deeper and Accounts understanding 2020 of respiratory biology Stock symbol: LSE:SNG www.synairgen.com Contents Introduction Highlights 2 Business Review Chairman's Statement 3 Strategic Report 5 Governance Synairgen's Founde... |
Show more